Justin Moser, MD
or call 480-323-1350
Insurance accepted
Insurance Plans
- AHCCCS Complete Care.
- AHCCCS CRS
- Dual-SNP
- 3 Tier Plans
- Banner Employees - Tier 2
- HMO
- PPO
- EPO
- Ameriben
- POS
- Indemnity
- CHS
- Alliance Network
- FEP (Standard, Basic and Blue Focus),
- Workers' Comp
- EverydayHealth PPO,
- BluePathway Plan 2 - Medicare Advantage
- BluePathway Plan 3 - - Medicare Advantage
- BlueJourney PPO - Medicare Advantage
- Classic/Plus - Medicare Advantage
- Medisun - Medicare Advantage
- All
- HMO
- PPO
- PPO Plus
- POS
- EPO
- LocalPlus
- Open Access Plan (OAP)
- CignaChoice Fund Access Plus
- Open Access Plus
- PPO
- RAN
- PPO
HonorHealth accepts most health insurance plans at its hospitals and physician offices. However, you need to contact your health insurance company to verify your coverage for individual physicians/providers and their physicians before you seek services.
Specialties
- Hematology Oncology
Credentials
-
Residency
Mayo Clinic -
Education
University of Iowa Roy J. and Lucille A. Carver College of Medicine -
Fellowship
University of Utah School of Medicine -
Board Certifications
American Board of Internal Medicine - Medical Oncology, American Board of Internal Medicine - Hematology
About
HonorHealth Cancer Care gives you access to an elite team of experts across the Valley. The physicians we collaborate with are nationally and internationally recognized.
Dr. Moser is a medical oncologist who specializes in the development of new cancer therapies to treat Melanoma, Squamous cell carcinoma of the Skin, Merkel cell carcinoma, Basal cell carcinoma and Uveal melanoma. Dr. Moser is one of the few physicians in Arizona to offer intratumoral injections for the treatment of Melanoma. He is involved in clinical trials testing new anti-cancer therapies for patients with all types of cancer, but a particular focus for patients with skin cancers.
Dr. Moser has a special focus on Uveal melanoma (eye cancer), and has an active translational research program focused on better understanding this rare tumor. He is actively developing new clinical trials and treatment options for patients with this disease.